FNCH vs. CHRS, CLLS, CRBP, CLYM, ZNTL, JSPR, EXOZ, TCRX, ELUT, and VNRX
Should you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Coherus Oncology (CHRS), Cellectis (CLLS), Corbus Pharmaceuticals (CRBP), Climb Bio (CLYM), Zentalis Pharmaceuticals (ZNTL), Jasper Therapeutics (JSPR), eXoZymes (EXOZ), TScan Therapeutics (TCRX), Elutia (ELUT), and VolitionRx (VNRX). These companies are all part of the "pharmaceutical products" industry.
Finch Therapeutics Group vs. Its Competitors
Finch Therapeutics Group (NASDAQ:FNCH) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 8.1% of Coherus Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Coherus Oncology has a consensus price target of $4.68, indicating a potential upside of 439.43%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than Finch Therapeutics Group.
In the previous week, Finch Therapeutics Group and Finch Therapeutics Group both had 1 articles in the media. Finch Therapeutics Group's average media sentiment score of 1.14 beat Coherus Oncology's score of 0.00 indicating that Finch Therapeutics Group is being referred to more favorably in the media.
Finch Therapeutics Group has a net margin of 0.00% compared to Coherus Oncology's net margin of -66.30%. Coherus Oncology's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.
Coherus Oncology has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.
Finch Therapeutics Group has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
Summary
Coherus Oncology beats Finch Therapeutics Group on 10 of the 14 factors compared between the two stocks.
Get Finch Therapeutics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Finch Therapeutics Group Competitors List
Related Companies and Tools
This page (NASDAQ:FNCH) was last updated on 7/9/2025 by MarketBeat.com Staff
Free FNCH Stock Alerts